U.S. stock market midday update: Propanc Biopharma down 11.59%, forward-looking statements raise market concerns about future performance

U.S. Stock Market Midday Update Propanc Biopharma fell 11.59%. Based on recent key news: On January 15, Propanc Biopharma announced that there are known and unknown risks and uncertainties in its forward-looking statements. These factors may lead to significant differences between actual results and expectations, increasing market concerns about the company's future performance, resulting in a decline in stock price. On January 15, content released by the company on GlobeNewswire indicated that the uncertainty of market conditions and the risk factors described in the SEC filings further exacerbated investor concerns, affecting stock price performance. The market remains vigilant about risks in the biopharmaceutical industry. Stocks with High Trading Volume in the Industry AbbVie fell 0.04%. Based on recent key news: On January 16, AbbVie announced the Phase III results of the EPCORE® DLBCL-1 trial and plans to discuss next steps with global regulatory agencies. This significant development drove volatility in AbbVie's stock price. Source: PR Newswire On January 15, AbbVie's strong growth in immunology and neuroscience supported a high single-digit compound annual growth rate in revenue. This growth expectation enhanced market confidence in AbbVie. Source: GlobalData On January 14, AbbVie signed an agreement with the U.S. government to lower Medicaid drug prices and committed to investing $100 billion in U.S. research and manufacturing over the next decade. This move helps alleviate tariff pressures, impacting stock price. Source: Economic Observer ImmunityBio rose 35.69%. Based on recent key news: On January 15, ImmunityBio received accelerated approval from the Saudi Food and Drug Authority for its Anktiva treatment for non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval drove the stock price up, demonstrating the company's expansion potential in the Middle East and North Africa. Source: WSJ On January 15, the company announced that net product revenue for the fourth quarter of 2025 reached approximately $38.3 million, a year-over-year increase of about 431%. This financial performance significantly boosted market confidence. Source: Business Wire On January 16, ImmunityBio announced that patient enrollment for its registrational QUILT-2.005 trial exceeded expectations, with completion anticipated in the second quarter of 2026. This progress further enhanced investor confidence in the company's future development. Source: Reuters Amgen rose 0.67%, with increased trading volume. Based on recent key news: On January 14, Goldman Sachs pointed out that Amgen's next-generation weight loss drug MariTide could be a significant catalyst for upward stock price movement. Goldman Sachs believes that Amgen's price-to-earnings ratio is below the industry average, with a target price of $400, expecting about a 30% upside in stock price The rising obesity rate drives demand for weight loss drugs, expanding the market size. Source: Goldman Sachs On January 15, Amgen announced the Phase II study results of MariTide at the J.P. Morgan Healthcare Conference, showing that participants maintained weight loss at low doses with fewer side effects. The results boosted market confidence in Amgen's stock. Source: Benzinga On January 15, analyst Phipps maintained an "Outperform" rating on Amgen, believing that the success of its key assets and late-stage pipeline assets will bring revenue growth potential. Source: Analyst report, the biotechnology sector performs strongly, with clear policy support. Stocks ranked at the top of the industry by market capitalization Gilead Sciences rose 2.35%. Based on recent key news: On January 16, Gilead Sciences showed a defensive trend recently, with limited intraday volatility, but signals of large capital repositioning gradually emerged. The rotation in the pharmaceutical sector accelerated, with market expectations for a new round of drug approvals or favorable industry policies, leading to a 2.35% increase in stock price. Source: Benzinga On January 15, Gilead Sciences oscillated around the key support of 116.88, with defensive main forces increasing positions, while short pressure remained unresolved, and the bullish position was resilient. Limited capital inflow, but blue-chip defensive funds showed resilience, driving the stock price up. Source: Benzinga On January 14, Bernstein analyst Courtney Breen maintained a buy rating on Gilead Sciences, with a target price of $135. The analyst rating had a positive impact on market confidence, boosting the stock price. Source: Bernstein, the rotation in the pharmaceutical sector accelerated, with limited capital inflow